2. Search Result
Search Result
Results for "

MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH

" in MedChemExpress (MCE) Product Catalog:

145

Inhibitors & Agonists

153

Peptides

1

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P5997
    XQ2B

    		Autophagy Cyclic GMP-AMP Synthase Inflammation/Immunology
    XQ2B is a specific cGAS inhibitor targeting protein-DNA interaction and phase separation. XQ2B markedly reduces ISD-induced Autophagy. XQ2B inhibits herpes simplex virus 1 (HSV-1)-induced antiviral immune responses and enhances HSV-1 infection .
    XQ2B
  • HY-P1045
    187-1, N-WASP inhibitor
    1 Publications Verification

    		 Arp2/3 Complex Others
    187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein .
    187-1, N-WASP inhibitor
  • HY-16129A
    CBP-501 acetate

    		Calmodulin MAP3K MAPKAPK2 (MK2) Checkpoint Kinase (Chk) Cancer
    CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer .
    CBP-501 acetate
  • HY-P1170
    N-terminally acetylated Leu-enkephalin

    Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH

    		 Opioid Receptor Neurological Disease
    N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.
    N-terminally acetylated Leu-enkephalin
  • HY-131990A
    MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH

    		ADC Linker Cancer
    MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH
  • HY-P10687
    H3B10-27(13/17αF)

    		RXFP Receptor Others
    H3B10-27(13/17αF) is an excellent scaffold for further developing reagent candidates and an important tool for understanding the physiological functions of the neuropeptide G protein-coupled receptor RXFP3, and it's very stable in serum .
    H3B10-27(13/17αF)
  • HY-P1045A
    187-1, N-WASP inhibitor TFA

    		Arp2/3 Complex Others
    187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein .
    187-1, N-WASP inhibitor TFA
  • HY-P3666
    [D-Phe2,6, Pro3]-LH-RH

    		GnRH Receptor Endocrinology
    [D-Phe2,6, Pro3]-LH-RH is a potent luteinizing hormone releasing hormone (LHRH) antagonist .
    [D-Phe2,6, Pro3]-LH-RH
  • HY-16129
    CBP-501

    		Calmodulin Checkpoint Kinase (Chk) MAPKAPK2 (MK2) MAP3K Cancer
    CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .
    CBP-501
  • HY-P2052
    AWL 60

    		Opioid Receptor Neurokinin Receptor Others
    AWL 60 is a compound with SP antagonist and weak opioid agonist properties, which can antagonize SP-agonists in vitro and attenuate the decrease in blood pressure caused by SP-agonists in vivo.
    AWL 60
  • HY-15664
    Bivalirudin TFA
    5+ Cited Publications

    		 Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .
    Bivalirudin TFA
  • HY-P1929
    Bivalirudin
    5+ Cited Publications

    		 Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .
    Bivalirudin
  • HY-P1985A
    Notch 1 TFA

    		Notch Cardiovascular Disease Cancer
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
    Notch 1 TFA
  • HY-P5098
    E(c(RGDfK))2

    		Integrin Cancer
    E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .
    E(c(RGDfK))2
  • HY-P5265
    Tetrapeptide

    		DNA/RNA Synthesis Metabolic Disease
    Tetrapeptide, an analogue of α-MSH, induces melanin synthesis. Tetrapeptide diminishes DNA damage by reducing the production of reactive oxidative species and enhancing repair of DNA photoproducts .
    Tetrapeptide
  • HY-P1107A
    Antisauvagine-30 TFA
    2 Publications Verification

    aSvg-30 TFA

    		 CRFR Neurological Disease
    Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF2 receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively .
    Antisauvagine-30 TFA
  • HY-P4236
    Gly-d-Phe

    		Carboxypeptidase Others
    Gly-d-Phe is an affinity ligand for Thermolysin (HY-P1748) . Gly-d-Phe can be used as the substrate of membrane dipeptidase (MDP) .
    Gly-d-Phe
  • HY-105077A
    Nemifitide diTFA

    INN 00835 diTFA

    		 5-HT Receptor Neurological Disease
    Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .
    Nemifitide diTFA
  • HY-P4541
    (D-Phe6,Leu-NHEt13,des-Met14)-Bombesin (6-14)

    		Bombesin Receptor Cancer
    (D-Phe6,Leu-NHEt13,des-Met14)-Bombesin (6-14) is a bombesin (BBN) antagonist and can be used for the research of cancer .
    (D-Phe6,Leu-NHEt13,des-Met14)-Bombesin (6-14)
  • HY-P1613
    Cyclo(Arg-Gly-Asp-D-Phe-Val)

    Cyclo(RGDfV); C(RGDfV)

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val)
  • HY-122542B
    PPACK TFA
    1 Publications Verification

    		 Thrombin PAI-1 Cardiovascular Disease
    PPACK TFA is potent, selective and irreversible thrombin inhibitor. PPACK TFA can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK TFA is also a plasminogen activator (rt-PA) inhibitor. PPACK TFA can inhibit the binding of rt-PA to plasma protease inhibitors .
    PPACK TFA
  • HY-P4561
    H-Pro-Thr-Glu-Phe-p-nitro-Phe-Arg-Leu-OH

    		Cathepsin Others
    H-Pro-Thr-Glu-Phe-p-nitro-Phe-Arg-Leu-OH is a water-soluble polypeptide that can serve as a substrate for cathepsin D, pepsin and pepsinogen. H-Pro-Thr-Glu-Phe-p-nitro-Phe-Arg-Leu-OH has potential applications in biochemical analysis .
    H-Pro-Thr-Glu-Phe-p-nitro-Phe-Arg-Leu-OH
  • HY-P2306
    Cyclo(Arg-Ala-Asp-D-Phe-Cys)

    		Biochemical Assay Reagents Others
    Cyclo(Arg-Ala-Asp-D-Phe-Cys), a cyclic RAD peptide, is a positive or negative control peptide of cyclo(Arg-Gly-Asp-D-Phe-Cys) (HY-P2300). Cyclo(Arg-Ala-Asp-D-Phe-Cys) can be used for multicolor ultrasound molecular imaging (USMI) .
    Cyclo(Arg-Ala-Asp-D-Phe-Cys)
  • HY-P10973
    Peptide R analogue 10

    		CXCR ERK Cancer
    Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .
    Peptide R analogue 10
  • HY-P10732
    DOTA-cyclo(RGDfK)

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-cyclo(RGDfK)
  • HY-P0031
    Cyclo(RADfK)
    1 Publications Verification

    		 Integrin Others
    Cyclo(RADfK) can be used as a control for Cyclo(-RGDfK) (HY-P0023) .
    Cyclo(RADfK)
  • HY-122542
    PPACK

    		Thrombin PAI-1 Cardiovascular Disease
    PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors .
    PPACK
  • HY-114437
    Fusion Inhibitory Peptide

    Z-D-Phe-Phe-Gly-OH; FIP; Virus Replication INHibitory Peptide

    		 Influenza Virus Infection
    Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH, FIP, Virus Replication Inhibitory Peptide) is a potent inhibitor of the virus replication, by inhibiting the membrane fusing activity of a viral glycoprotein .
    Fusion Inhibitory Peptide
  • HY-P3567
    (p-Iodo-Phe7)-ACTH (4-10)

    		Melanocortin Receptor Neurological Disease
    (p-Iodo-Phe7)-ACTH (4-10) is a adrenocorticotrophic hormone (ACTH) derivative, which is produced and secreted by the anterior pituitary gland. (p-Iodo-Phe7)-ACTH (4-10) serves as a melanocortin (MC) receptor antagonist and inhibits α-melanocyte-stimulating hormone (α-MSH)-induced excessive grooming behavior in rats .
    (p-Iodo-Phe7)-ACTH (4-10)
  • HY-123275
    H-D-Phe-Pip-Arg-pNA

    S-2238

    		 Fluorescent Dye Others
    H-D-Phe-Pip-Arg-pNA (S-2238), a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA is sensitive, accurate, and easy to perform .
    H-D-Phe-Pip-Arg-pNA
  • HY-P1185
    Antagonist G

    		Vasopressin Receptor Apoptosis Cardiovascular Disease Cancer
    Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .
    Antagonist G
  • HY-P1613A
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

    Cyclo(RGDfV) TFA; C(RGDfV) TFA

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
  • HY-P1185A
    Antagonist G TFA

    		Vasopressin Receptor Apoptosis Cancer
    Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .
    Antagonist G TFA
  • HY-P4907
    RGD Negative Control

    		Integrin Others
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-P1159
    [D-p-Cl-Phe6,Leu17]-VIP

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    [D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors .
    [D-p-Cl-Phe6,Leu17]-VIP
  • HY-P1159A
    [D-p-Cl-Phe6,Leu17]-VIP TFA

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    [D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors .
    [D-p-Cl-Phe6,Leu17]-VIP TFA
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Biochemical Assay Reagents Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-P2028
    BIM 21009

    		GnRH Receptor Cancer
    BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .
    BIM 21009
  • HY-P1106
    K41498

    		CRFR Cardiovascular Disease
    K41498 is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 can be used for hypotension study .
    K41498
  • HY-P1338A
    PL-017 TFA

    		Opioid Receptor Neurological Disease
    PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .
    PL-017 TFA
  • HY-P3659
    (D-Phe7)-α-MSH

    		Melanocortin Receptor Cancer
    (D-Phe7)-α-MSH is an α-MSH analogue .
    (D-Phe7)-α-MSH
  • HY-P10224A
    G7-18NATE TFA

    		EGFR Cancer
    G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines .
    G7-18NATE TFA
  • HY-P1106A
    K41498 TFA

    		CFTR Cardiovascular Disease
    K41498 TFA is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 TFA can be used for hypotension study .
    K41498 TFA
  • HY-P1338
    PL-017

    		Opioid Receptor Neurological Disease
    PL-017 is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .
    PL-017
  • HY-P4107
    Bilaid C

    		Opioid Receptor Neurological Disease
    Bilaid C, a tetrapeptide, can be isolated from the Australian estuarine isolate of Penicillium sp. MST-MF667. Bilaid C is also a potent and selective μ-Opioid Receptor (MOPr) agonist (Ki=210 nM, hMOPr) .
    Bilaid C
  • HY-W755425
    Senktide TFA

    		Neurokinin Receptor Neurological Disease
    Senktide TFA is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC50=0.5-3 nM). Senktide TFA less potently agonizes the NK1 receptor (EC50=35 µM). Senktide TFA is promising for research of neurological disease .
    Senktide TFA
  • HY-103287
    [D-Phe12,Leu14]-Bombesin

    		Bombesin Receptor Cancer
    [D-Phe12,Leu14]-Bombesin is an antagonist of Bombesin Receptor. [D-Phe12,Leu14]-Bombesin can be used for the research of cancer .
    [D-Phe12,Leu14]-Bombesin
  • HY-103282
    [D-Phe12]-Bombesin

    		Bombesin Receptor Others
    [D-Phe12]-Bombesin is a derivative of Bombesin (HY-P0195) and an antagonist for bombesin receptor with Ki of 4.7 μM. [D-Phe12]-Bombesin inhibits the Bombesin (HY-P0195)-induced amylase release, with IC50 of 4 μM .
    [D-Phe12]-Bombesin
  • HY-P1714
    Apraglutide

    FE 203799

    		 GLP Receptor Metabolic Disease
    Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .
    Apraglutide
  • HY-P3043
    Bilaid A

    		Opioid Receptor Neurological Disease
    Bilaid A is a μ-opioid receptor agonist that can be extracted from Penicillium. The Ki value is 3.1 μM. Bilaid A can be used in pain research .
    Bilaid A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: